New Mountain Capital Backs Commonwealth Associates in Healthcare PE Play

New Mountain Capital has made a growth equity investment in Commonwealth Associates, a national provider of radiology technology management services, the firms announced Monday. The deal arrives as private equity continues to hunt for consolidation opportunities in fragmented healthcare services markets — particularly in infrastructure plays that sit adjacent to, but outside of, direct patient care.

Financial terms weren't disclosed. But the transaction structure — a growth equity stake rather than a full buyout — suggests New Mountain sees runway in Commonwealth's existing business model without needing to tear it apart and rebuild. That's notable in a sector where PE healthcare deals often trigger immediate operational overhauls and margin squeezes.

Alongside the investment, Commonwealth appointed Dr. Hisham Mahmoud as chairman of the board. Mahmoud brings a track record from the radiology equipment and services world, most recently as CEO of RadNet, where he led a national network of outpatient imaging centers. His involvement signals this isn't just a financial engineering play — New Mountain appears to be backing a thesis that Commonwealth can scale in a market ripe for consolidation.

Commonwealth manages radiology technology infrastructure for hospitals and healthcare systems across the country — the behind-the-scenes machinery that keeps imaging departments running. Think equipment procurement, maintenance contracts, technology lifecycle management, and compliance with evolving regulatory standards. It's unglamorous work that healthcare systems increasingly prefer to outsource rather than manage in-house.

The radiology services market has been fragmenting for years. Hospitals face constant pressure to reduce capital expenditure while maintaining cutting-edge diagnostic capabilities. Radiology equipment — MRI machines, CT scanners, X-ray systems — carries price tags in the millions and requires specialized technical expertise to maintain. That creates an opening for third-party managers who can spread costs across multiple facilities and negotiate better terms with equipment manufacturers.

New Mountain has been methodically building positions in healthcare infrastructure over the past decade. The firm's portfolio includes stakes in revenue cycle management companies, healthcare IT platforms, and specialized services providers — businesses that plug into the healthcare system without directly delivering care. It's a strategy designed to capture margin while avoiding the clinical risk and regulatory heat that comes with owning hospitals or physician practices. According to PitchBook data, healthcare services deals represented 22% of all U.S. private equity transactions in 2025, up from 18% in 2023.

Commonwealth's positioning is particularly attractive because it sits in the capital equipment layer — a recurring revenue model tied to long-term hospital contracts. Once a healthcare system outsources radiology tech management, switching costs are high. Equipment lives on multi-year replacement cycles, service contracts auto-renew, and institutional knowledge becomes embedded in the vendor relationship.

The company doesn't own imaging centers or employ radiologists. It manages the technology backbone, which means it avoids the physician employment regulations and certificate-of-need restrictions that complicate other healthcare services businesses. That's a cleaner value proposition for growth equity — scalable, capital-efficient, and less exposed to clinical liability.

Dr. Hisham Mahmoud's appointment as chairman isn't window dressing. He spent more than a decade at RadNet, eventually running the largest outpatient imaging network in the U.S. Before that, he held leadership roles at Siemens Healthineers and Philips Healthcare — the equipment manufacturers that Commonwealth now helps hospitals manage relationships with.

That's the kind of resume that suggests operational build-out, not just financial oversight. Mahmoud knows how imaging networks scale, how equipment contracts get negotiated, and where margin lives in radiology services. His involvement hints that New Mountain's thesis involves geographic expansion and potentially acquisitive growth — rolling up smaller regional players or adding adjacent service lines.

In a statement, Mahmoud called Commonwealth "uniquely positioned to address the evolving needs of healthcare providers." The phrasing is standard-issue PE speak, but the subtext matters: hospitals are under financial pressure, imaging volumes are growing as the population ages, and technology refresh cycles are accelerating. Someone has to manage that complexity. Commonwealth — and now New Mountain — is betting it'll be them.

Commonwealth's existing management team remains in place. Founder and CEO Brian Kelly will continue leading day-to-day operations. That's typical for growth equity deals, where the goal is to fuel expansion rather than replace leadership. New Mountain's capital likely funds geographic expansion, technology platform upgrades, and potentially acquisition activity to consolidate the fragmented market.

Radiology technology management sits at the intersection of healthcare delivery and capital equipment markets. The sector is fragmented, with regional players and in-house hospital departments dominating. National-scale providers remain rare, which is exactly the kind of market structure that attracts growth equity looking for consolidation plays.

The U.S. medical imaging services market was valued at approximately $16.4 billion in 2024, according to Grand View Research, with expectations to grow at a 6.2% CAGR through 2030. Volume drivers are straightforward: aging demographics, rising chronic disease prevalence, and technological advances that make imaging a first-line diagnostic tool for more conditions.

But owning and operating imaging equipment is capital-intensive and operationally complex. A single MRI machine costs $1-3 million. CT scanners run $500K-2M. Equipment has a useful life of 7-10 years, after which it needs replacement or significant refurbishment. Maintenance contracts, calibration requirements, and regulatory compliance add ongoing costs.

For hospitals already running tight margins — and most are — outsourcing that complexity to a specialist makes financial sense. Commonwealth effectively turns capital expenditure into an operating expense, spreads risk across its client base, and leverages purchasing power with equipment manufacturers. It's a business model that scales well, which is why it caught New Mountain's attention.

Commonwealth isn't the only player in radiology tech management, but the market remains unconsolidated. Competitors include Philips Healthcare's service divisions, Siemens Healthineers' managed equipment services, and smaller regional outfits. Most hospitals still manage radiology equipment in-house, which means the total addressable market for outsourced services is still early in its penetration curve.

The largest opportunity may be in mid-sized hospital systems — institutions big enough to have multiple imaging departments but too small to justify dedicated in-house technology management teams. Those are the accounts where Commonwealth can deliver immediate value through standardized processes, better equipment utilization, and reduced downtime.

New Mountain Capital manages over $45 billion in assets and has been active in healthcare services for more than a decade. The firm's healthcare portfolio includes companies like Innovaccer (healthcare data platform), Appriss Health (prescription monitoring), and SOC Telemed (telemedicine infrastructure). The through line: infrastructure plays that serve healthcare systems without directly providing clinical care.

That strategy reflects a calculated risk-return calculus. Clinical businesses face regulatory scrutiny, reimbursement risk, and potential liability. Infrastructure businesses face none of those — or at least far less of them. They're also stickier, since switching costs for technology platforms and service contracts are high.

The Commonwealth deal fits that pattern precisely. New Mountain isn't buying a radiology group or an imaging center chain — it's backing the technology layer that makes those businesses run. If imaging volumes grow, Commonwealth benefits. If hospitals consolidate, Commonwealth can consolidate service contracts. If equipment gets more complex and expensive, Commonwealth's value proposition strengthens.

The growth equity structure also matters. Rather than loading the company with acquisition debt — the classic leveraged buyout model — New Mountain is providing expansion capital while leaving the existing capital structure intact. That suggests the firm sees organic growth potential and wants to preserve financial flexibility for add-on acquisitions down the line.

Growth equity deals in healthcare services typically target companies with $20-100 million in revenue that have proven unit economics but need capital to scale. Commonwealth likely falls somewhere in that range, though the company hasn't disclosed financials. The fact that New Mountain took a stake rather than buying the company outright suggests the founders and management team retained meaningful equity — a structure designed to keep them motivated through the next growth phase.

Mahmoud's appointment as chairman, rather than CEO, also signals continuity. He's there to provide strategic guidance and open doors with hospital systems and equipment manufacturers, not to run day-to-day operations. That's a setup that works when the existing management team is strong and the business model is sound — you're adding horsepower, not replacing the engine.

Private equity's expansion into healthcare infrastructure has drawn scrutiny from regulators and researchers concerned about consolidation's impact on costs and quality. The Commonwealth deal sits in a less controversial segment — it's not physician practice roll-ups or hospital acquisitions — but the broader trend deserves attention.

A 2024 study published in JAMA found that private equity ownership of healthcare services businesses was associated with higher prices but mixed quality outcomes. The calculus changes depending on the subsector. Revenue cycle management and IT platforms — where PE has been active for years — generally show efficiency gains. Physician practices and nursing homes — where PE ownership is more controversial — show more mixed results.

Radiology tech management sits somewhere in between. Done well, it reduces costs for hospitals and improves equipment uptime. Done poorly — or optimized purely for margin — it could lead to deferred maintenance, longer equipment replacement cycles, and ultimately degraded imaging quality. The question is whether New Mountain's incentives align with long-term infrastructure quality or short-term cost extraction.

The presence of Mahmoud suggests a longer time horizon. You don't bring in a former RadNet CEO to strip costs — you bring him in to build a national platform. That likely means Commonwealth will pursue acquisitions, expand into adjacent service lines, and potentially invest in proprietary technology platforms that increase switching costs for clients.

If Commonwealth follows the standard PE healthcare playbook, expect a series of add-on acquisitions over the next 18-24 months. The fragmented radiology services market offers plenty of targets — regional equipment management firms, specialized imaging IT companies, and possibly distressed imaging center operators whose technology assets could be folded into Commonwealth's platform.

New Mountain's capital provides the currency for those deals. The firm can offer smaller competitors liquidity, scale, and access to better equipment pricing. In exchange, it builds a national footprint that becomes harder for hospitals to ignore. At sufficient scale, Commonwealth could negotiate directly with Siemens, GE Healthcare, and Philips as a major distribution and service partner — flipping the relationship from vendor-dependent to vendor-influential.

The endgame? Either an exit to a larger healthcare services conglomerate — think UnitedHealth's Optum division or CVS Health's services arm — or a continuation vehicle where New Mountain holds the asset longer-term and takes it public. Given the recurring revenue profile and long contract durations, Commonwealth could be positioned as a healthcare infrastructure REIT analogue — steady cash flows, predictable growth, and a story that public markets understand.

Or New Mountain could sell to a strategic buyer looking to vertically integrate. An imaging center chain like RadNet or a hospital system looking to bring technology management in-house at scale. Either path requires Commonwealth to hit growth targets over the next 3-5 years, which is where Mahmoud's operator background becomes critical.

For hospital CFOs watching this deal, the calculus is straightforward: outsourcing radiology tech management to a PE-backed consolidator offers financial predictability but introduces new dependencies. Commonwealth's pitch is compelling — fixed costs, better equipment uptime, access to latest technology without capital outlay. The risk is lock-in. Once you've outsourced radiology infrastructure, bringing it back in-house is expensive and disruptive.

That's not necessarily bad. Hospitals outsource plenty of functions — food service, janitorial, IT — without catastrophic results. The question is whether Commonwealth's incentives stay aligned with hospital needs as New Mountain pushes for growth and margin expansion. Early-stage growth equity deals tend to prioritize customer acquisition and market share. Later-stage deals prioritize margin optimization and EBITDA growth. Hospitals signing contracts today are betting on the former, but they'll live with the latter.

The presence of Dr. Mahmoud offers some reassurance. He's been on the hospital side of these negotiations and understands the importance of maintaining relationships and delivering consistent service quality. Whether that perspective survives the pressure to hit PE return targets is the open question.

For now, Commonwealth and New Mountain are in the honeymoon phase — announcing the partnership, signaling growth ambitions, and positioning the company as a rising player in a consolidating market. The real test comes 18 months from now, when acquisition integration is underway, contract renewals are up for negotiation, and the margin pressure starts building. That's when we'll learn whether this deal was about building a sustainable healthcare infrastructure business or just financial engineering with a stethoscope.

The Commonwealth deal is a data point in a larger trend — private equity moving deeper into healthcare's operational backbone. Not hospitals, not physician practices, but the pipes and platforms that make the system run. Revenue cycle management, claims processing, care coordination software, credentialing services, and now radiology technology management.

It's a land grab. And the prize is recurring revenue streams tied to long-term contracts in a sector that isn't going away. Healthcare spending in the U.S. will hit $6.2 trillion by 2028, according to CMS projections. Someone's going to capture the margin in the middle — the layer between providers and patients where technology, logistics, and administration live. New Mountain is betting that Commonwealth can be one of those middlemen.

Whether that benefits the healthcare system as a whole depends on execution. If Commonwealth uses New Mountain's capital to genuinely improve hospital efficiency and equipment quality, it's a win-win. If it becomes a toll booth extracting rent from a captive customer base, it's a different story. We won't know which until the next deal cycle — and by then, the consolidation will be complete.

For now, the smart money is on infrastructure. The unglamorous, capital-intensive, contract-heavy businesses that nobody notices until they break. That's where Commonwealth lives. And with New Mountain's backing and Mahmoud's Rolodex, it's positioned to become the brand hospitals call when their imaging equipment needs managing — whether they want to or not.